First Light Signs Contract with the Biomedical Advanced Research and Development Authority
Bedford, MA (October 2015) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today a contract with the Biomedical Advanced Research and Development Authority to develop rapid, sensitive, and easy-to-use anthrax tests. The contract supports the project with $5.5 million over…
First Light Closes $3.5M Series A Financing
Bedford, MA (September 2015) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today closure of $3.5 Million in series A financing. The financing will be used to continue developing tests to rapidly detect hospital infections and determine their susceptibility to…
First Light Awarded a $4M 4-year NIH RO1 Award for Rapid ID and AST Tests for Hospital Infections
Bedford, MA (February 2015) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today that they had been awarded an NIH RO1 award. The 4-year, $4 million award will be used for developing tests to rapidly detect hospital infections and determine…
First Light Granted European Patent for “Method for Detecting Analytes”
Bedford, MA (December 2013) – First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today that they had been granted the European Patent for “Method for detecting analytes”. The patent number is EP2340300. About First Light Biosciences Based in Bedford, Massachusetts, First…
First Light Granted US Patent for “Rapid and Sensitive Detection of Cells and Viruses”
Bedford, MA (September 2011) – First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today that they had been granted a United States Patent for “Rapid and Sensitive Detection of Cells and Viruses. The patent number is US8021848. About First Light Biosciences…
First Light awarded a $3M 3-year Phase II NIH SBIR grant to develop a benchtop automated platform for hospital clinical microbiology laboratories
Bedford, MA (March 2011) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today the award of a phase II NIH SBIR grant. The 3-year, $3 million grant will be used to develop a benchtop automated platform for hospital clinical microbiology…
First Light Granted European Patent for “Rapid and Sensitive Detection of Molecules”
Bedford, MA (March 2009) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today that they had been awarded an NIH Phase II SBIR grant. The 3-year, $3 million grant will be used to develop an automated platform to accommodate the…
First Light Awarded a $600K, 2-year NIH Phase I SBIR Grant
Bedford, MA (September 2008) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today that they had been awarded an NIH Phase I SBIR grant. The 2-year, $600,000 grant will be used to develop the MultiPath™ imaging technology for rapid, sensitive,…
First Light Awarded a $300K NIH Phase I SBIR Grant
Bedford, MA (August 2008) – First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today that they had been awarded an NIH Phase I SBIR grant. The $300,000.00 award will be used to develop the MultiPath™ imaging technology for highly sensitive detection…